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INTRODUCTION
Alzheimer’s disease (AD) affects about 4-7% of people over
the age of 65 yr in Korea (1). As patients with AD progres-
sively lose autonomy with a functional decline, caregivers ex-
perience a progressively increasing care burden with concur-
rent social isolation. 
Galantamine is a tertiary alkaloid with a proposed dual
mode of action: competitive inhibition of acetylcholinesterase
(AChE) and allosteric modulation of nicotinic receptors (2).
The long-term efficacy of galantamine in delaying the decline
in cognitive function, activities of daily living, and behav-
ioral disturbances has recently began to be reported (3, 4).
However, few studies have focused on the long-term eco-
nomic and clinical benefits of galantamine. This 52-week
prospective study aims to investigate the economic and clin-
ical effects of galantamine, especially focusing on the func-
tional capacity, caregiver time, and resources used in patients
with mild to moderate AD in a Korean population. 
MATERIALS AND METHODS
Study design
The rationale, methods, and results of the 16-week double-
blind, community-controlled trial have been described else-
where (5). As with the original 16-week study, the extended
52-week prospective health economic study was also quasi-
experimentally designed with a galantamine group (multi-
center, randomized, double-blind, parallel-group from 3 study
centers in Korea) and a community AD cohort as a control
group. This prospective study evaluated the impact of galan-
tamine treatment on costs and outcomes of caring for patients
with mild to moderate AD who lived at home. The same
methodology (i.e., same inclusion/exclusion criteria, same
rating scales, and raters who were trained at the same sessions)
was used for the galantamine group and the control group
without treatment from a community AD cohort. Galan-
tamine was administered orally by random assignment (8,
16, or 24 mg/day) according to the clinically recommended
4-week dose escalation. Subjects with galantamine treatment
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Economic and Clinical Benefits of Galantamine in the Treatment of
Mild to Moderate Alzheimer’ s Disease in a Korean Population: 
A 52-Week Prospective Study
To evaluate the impact of galantamine treatment on the function, caregiver time, and
resource used in the treatment of patients with mild to moderate Alzheimer’s disease
(AD), costs and outcomes were evaluated during a 52-week prospective, random-
ized, double-blind, community-controlled trial of galantamine. Patients received either
galantamine treatment (n=72) or no treatment (n=66). The analysis was performed
from a societal perspective. Galantamine treatment reduced time spent caring for
the patients and maintained improved functional capacity, whereas, when no treat-
ments were given, a great increase in caregiver time and progressive functional dete-
riorations were observed. Saved caregiver time was equivalent to 113 working days
per year. After 52 weeks, mean total annual costs per patient were 14,735,000 Korea
Won (KRW) (USD 12,315) for patients with galantamine treatment and 25,325,000
KRW (USD 21,166) for patients without treatment. Adjusted annual cost saving of
galantamine treatment was 6,428,000 KRW (USD 5,372) when compared to no
treatment (p=0.0089). Galantamine had a beneficial effect not only to slow func-
tional decline in patients with mild to moderate AD, but also to save a substantial
amount of costs, closely related to reduction in caregiver burden and decrease in
caregiver time.
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Alzheimer Disease; Function; Benefit; Economy
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had safety and efficacy evaluations at baseline (week 0) and
after 4, 8, 16, 24, 38, and 52 weeks, while economic data
were collected at baseline and after 16, 24, 38, and 52 weeks.
The community control group without treatment had safe-
ty, efficacy, and health economic evaluation at baseline (week
0) and after 24 and 52 weeks.
Written informed consent was obtained from each patient
and caregiver. This study was conducted in accordance with
the Declaration of Helsinki and its subsequent revisions, and
was approved by ethics committees at each center.
Patients
Patients were included in the study if they were aged over
50 yr, had suffered from AD diagnosed according to the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) (6), and probable AD according to the
National Institute of Neurological and Communicative Dis-
orders and Stroke and the Alzheimer’s Disease and Related
Disorders Association (NINCDS/ADRDA) (7), have mild
to moderate AD (the Mini-Mental State Examination [MMSE]
[8] scores of 10 to 22; the Alzheimer’s Disease Assessment
Scale [9]; and 11-item cognitive subscale [ADAS-cog/11]
score ≥14), had a history of cognitive decline with a gradual
onset of symptoms and progression over 6 months or more
before baseline, and had responsible caregivers who would
be able to provide necessary information about the patient.
Patients were excluded if they had evidence of any neurode-
generative disorder other than AD; primary dementia of vas-
cular origin, and secondary dementia caused by inflammato-
ry diseases, infections, intoxication, metabolic diseases, or
tumors. 
Outcome measures
Demographic and clinical data were measured as outcomes
that might influence the costs of caring for AD patients who
live at home: all the following outcomes were used as inde-
pendent variables in primary statistical analyses: 1) demo-
graphic and socio-economic characteristics of patients and
caregivers; 2) AD characteristics (e.g., time since diagnosis of
cognitive abnormality); 3) group (the galantamine group vs.
the community control group); 4) functional decline assessed
using the Disability Assessment for Dementia (DAD) scale,
Korean version (10, 11). The 40-item DAD, based on inter-
views with the caregiver, measures basic activities of daily
living (ADLs) (BADLs) and instrumental ADLs (IADLs), as
well as the specific components required for the completion
of each ADL (initiation, planning and organization, and effec-
tive performance); scores range from 0 to 100. A higher score
indicates a better functional capacity; 5) cognitive impair-
ment assessed using the ADAS-cog/11, Korean version (9,
12). A higher score indicates worse cognitive function; 6)
behavioral disturbance assessed using the Behavior Patholo-
gy in Alzheimer’s disease Rating Scale, Korean version (BE-
HAVE-AD) (13, 14). A higher score indicates more frequent
and/or more serious behavioral disturbances; 7) severity of AD
assessed using the Global Deterioration Scale (GDS) (15). A
higher stage indicates more advanced state of AD.
Costs
Data on the resource use of all medical and other commu-
nity service were collected prospectively for each patient.
Resource use was measured using the adapted version of the
Client Service Receipt Inventory (CSRI) (16). Primary care-
givers were asked to provide details of services and costs that
patients had used during the previous 2 months, which was
deemed to allow for relatively accurate recall and also to be
representative of service use, by face-to-face interview. Re-
sources used included hospital and primary care services (in-
patient, out-patient, day hospital, emergency room, commu-
nity mental health center, general practitioner, community
practice nurse, and medication), social care services (social
worker, day care center, meals on wheels, and home care),
accommodation, out-of-pocket purchase for self-support (pri-
vate hire of a paid caregiver or a paid home helper, health
food and supplement etc), caregiver time, and missed work
of caregiver. Indirect costs were calculated using a replace-
ment cost approach. Caregiver time assessed using the care-
giver time section of the Resource Utilization in Dementia
(RUD) questionnaire (17). Informal caregiver time was val-
ued at the 2002 average household help wage in Korea, equiv-
alent to Korean Won (KRW) 6,250 (US dollar [USD] 5.22)
per hour (18). The total costs were calculated by adding each
cost for resource used by each patient. Unit costs for the year
of 2002 are obtained from nationwide sources in Korea (19-
22). All unit costs are reported in 2002 values using wage
and price indices from national statistics offices or the con-
sumer price index.
Economic evaluation
The analysis was performed from a societal perspective.
The primary economic analytical technique initially used
was a cost-consequence analysis with a list of multiple, clin-
ically important between-group differences in costs and out-
comes. The intent-to-treat population was used in the anal-
yses. Costs are given in KRW and USD using a conversion
rate of 1,196.5, the mean value of the fiscal year of 2002. No
discounting was necessary, since the economic evaluation had
a time horizon of 1 yr. 
Sensitivity analysis
The following sensitivity analyses were conducted. First, to
account for patients withdrawing from the study premature-
ly, the conventional last-observation-carried-forward (LOCF)12 G.-H. Suh, H.Y. Jung, C.U. Lee, et al.
approach was supposed to impute missing values instead of
advanced statistical methods using the mixed model or gen-
eralized estimating equation (GEE) regression analyses for
this study. Second, the effects of caregiver time on costs were
tested by the use of an alternative cost per hour (-50% to
+50%) instead of KRW 6,250 (USD 5.22) per hour.
Statistical analysis
Univariate analyses were used to calculate the basic statis-
tics of all variables and to test the normality of dependent
variables. Statistical comparisons were performed for the
galantamine group versus the control group using one-way
analysis of variance (ANOVA) for continuous variables and
the Cochran-Mantel-Haenszel test for categorical variables. 
For the analysis of the caregiver time, a maximum of 16
hr/day was allowed for each subject for one’s baseline time.
The same rule was applied to the assessment of time spent
caring for disabled function at 24 and 52 weeks. We supposed
that at least 8 hr should be used for caregiver’s personal ADL.
Where values of more than 16 hr/day were recorded for care-
giver time, a truncation to 16 hr/day was assigned in the anal-
ysis. To test the statistical significance of sequential changes,
we conducted multivariate analyses (applying a mixed model
for continuous dependent variables [i.e., caregiver time, and
DAD-K]) by using the following independent variables as
covariates: times of repeated assessment (0, 4, 8, 16, 24, 38,
and 52 weeks), dose (0, 8, 16, and 24 mg) and individual
indicators (e.g., patient and caregiver age, duration of for-
mal education, and functional capacity). 
Due to the skewed distribution of cost data, a generalized
linear model using the GEE method for non-normal distri-
bution (gamma distribution) was used when including cost
data. All statistical analyses were two-sided and performed
at the 0.05 significance level.
RESULTS
Patient and caregiver characteristics at baseline (Table 1)
The mean age of patients (N=138) who were included in
the 52-week study was 75.5 (SD=8.5) yr [galantamine group
74.0 (SD=8.2) yr; control group 76.8 (SD=8.5) yr] and 75.4
% were female. The mean duration of formal education was
4.0 (SD=4.6) yr [galantamine group 6.0 (SD=5.0) yr; con-
trol group 1.8 (SD=2.8) yr]. The mean time since diagnosis
of cognitive abnormality was 3.3 (SD=2.9) yr [galantamine
group 3.0 (SD=1.9) yr; control group 3.7 (SD=3.8) yr]. Pati-
ents in the two groups were comparable with respect to gen-
der distribution, time since diagnosis of cognitive abnormal-
ity, the total MMSE score, and the severity of dementia assess-
ed using the GDS. There were imbalances in age and dura-
tion of formal education of two groups. Patients in the galan-
tamine group were more like to be younger (p=0.0272) and
more educated (p<0.0001). While caregivers (N=138) in
the two groups were comparable with respect to gender dis-
tribution, caregivers in the galantamine group were more
likely to be younger (p<0.0001) [galantamine group 49.4
(SD=13.9) yr; control group 63.2 (SD=12.5) yr]. Therefore,
all the significantly different patient and caregiver charac-
teristics were included in the statistical models to assess any
Case
16-Week Comparison (n=300)
Characteristics
(n=234)
Control
(n=66)
p
�
52-Week Comparison (n=138)
Characteristics
(n=72)
Control
(n=66)
p
�
Patients
Women, n (%) 178 (76.1%) 50 (75.6%) 0.9854 54 (75.0%) 50 (75.8%) 0.9181
Age (yr) 74.6±7.4 76.8±8.5 0.0201 74.0±8.2 76.8±8.5 0.0272
Duration of formal education (yr) 5.5±4.4 1.8±2.8 <0.0001 6.0±5.0 1.8±2.8 <0.0001
Time since diagnosis of cognitive  3.1±2.1 3.7±3.8 0.1041 3.0±1.9 3.7±3.8 0.1875
abnormality (yr)
Total MMSE score 16.4±3.3 15.4±3.9 0.0520 16.3±3.4 15.4±3.9 0.1515
Global Deterioration Scale (GDS), n (%)* 0.2734 0.7983
Stage 4 156 (67.0%) 43 (66.2%) 42 (59.2%) 43 (66.2%)
Stage 5 48 (20.6%) 8 (12.3%) 15 (21.1%) 8 (12.3%)
Stage 6 29 (12.4%) 13 (20.0%) 14 (19.7%) 13 (20.0%)
Stage 7 0 1 ( 1.5%) 0 1 ( 1.5%)
Caregivers
Women, n (%) 152 (65.0%) 39 (59.1%) 0.3823 44 (61.1%) 39 (59.1%) 0.8094
Age (yr) 51.4±13.9 63.2±12.5 <0.0001 49.4±13.9 63.2±12.5 <0.0001
Table 1. Baseline demographic and clinical characteristics of two study populations 
Values are expressed as mean [standard deviation] unless otherwise indicated.
MMSE, mini-mental state examination. *Data in the variable GDS has two missing information (N=298), one for each group; 
� data were analyzed between
the community clinical trial group and the naturalistic community study group by means of one-way analysis of variance, except for gender and GDS
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effect on the dependent variables. 
These statistics were not different when applied to the
subjects of original clinical trial (N=300) (Table 1). Baseline
characteristics of patients and caregivers were not statistical-
ly significantly different between two galantamine groups
of original 16-week clinical trial (n=234) and the 52-week
trial (n=72).
Clinical efficacy
After 52 weeks of treatment, results of mixed model anal-
yses showed significantly reduced caregiver times caring for
BADLs and IADLs in the galantamine group, relative to
baseline (BADLs, F=24.63, p<0.0001; IADLs, F=14.84, p<
0.0001) and compared with the control group (BADLs, F=
9.62, p=0.0024; IADLs, F=10.51, p=0.0016) (Fig. 1). The
mean reduction in the caregiver time caring for BADLs from
baseline were 3.4 hr per month for the galantamine group,
whereas the subjects in the community control group requir-
ed an average of 39.6 more hour of caregiver time per month
(Fig. 1). It means that the 52-week galantamine treatment can
save 85 min per day in caring for BADLs when compared
to no treatment. The mean reduction in the caregiver time
caring for IADLs from baseline were 3.3 hr per month for
the galantamine group, whereas subjects in the community
control group required an average of 29.2 more hours of care-
giver time per month (Fig. 1). It means that the 52-week
galantamine treatment can save 64 min per day in caring
for IADLs when compared to no treatment. At the end of
52 weeks, caregiver time for BADLs and IADLs in the galan-
tamine group was reduced 6.7 hr per month, whereas it in-
creased by 68.8 hr per month in the community control group
compared to baseline (F=10.01, p=0.0019). It means that
the 52-week galantamine treatment can save 149 min per
day in caring for both BADLs and IADLs when compared
to no treatment. 
After 52 weeks of treatment, results of a mixed model anal-
ysis of the mean total score of DAD-K showed improved func-
tional capacity in the galantamine group, relative to base-
line (F=13.89, p<0.0001) and compared with the control
group (F=16.89, p<0.0001). The mean improvement from
baseline was 6.1 points for the galantamine group, whereas
the community control group deteriorated by a mean of 17.4
points (Fig. 2). Similarly, statistically significant improve-
ment in mean BADLs score of the DAD-K was also observed
in galantamine groups after 52 weeks, relative to baseline
(F=7.61, p<0.0001) and compared with the control group
(F=5.05, p=0.0262). The mean BADLs score improvement
in the galantamine group was 0.8 points, whereas the con-
trol group’s score deteriorated by a mean of 14.8 points. The
mean IADLs score of the DAD-K was also statistically signif-
icantly improved in the galantamine group after 52 weeks,
relative to baseline (F=9.61, p<0.0001) and compared with
the control group (F=14.11, p<0.0001). The mean IADLs
score improvement in the galantamine group was 10.1 points,
whereas the control group’s score deteriorated by a mean of
19.3 points.
After 52 weeks of treatment, results of a mixed model anal-
ysis of the ADAScog/11K showed improved cognitive func-
tion in the galantamine group, relative to baseline (F=44.54,
p<0.0001) and compared with the control group (F=36.61,
p<0.0001). The mean improvement from baseline was 4.5
points for the galantamine group, whereas the community
control group deteriorated by a mean of 14.3 points. 
After 52 weeks of treatment, results of a mixed model anal-
ysis showed improved behavior measured by the BEHAVE-
AD in the galantamine group, relative to baseline (F=33.89,
p<0.0001) and compared with the control group (F=21.28,
p<0.0001). 
However, the result of a mixed model analysis did not
showed a between-group (F=1.88, p=0.1355) or between-
time difference (F=1.68, p=0.1952) in severity of dementia
measured by the GDS.
M
e
a
n
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
S
E
)
-10
0
10
20
30
40
50
06 1 2
Duration of treatment (months)
Decline
*
Galantamine
Improvement
Caregiver time of for basic ADLs (hr/month)
Fig. 1. Mean change (standard error) over time from baseline in
caregiver time spent caring for disabled function.
Community control
*Mixed model; p=0.0024 galantamine vs. control
M
e
a
n
 
c
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
(
S
E
)
-20
-10
0
10
20
30
40
06 1 2
Duration of treatment (months)
Decline
*
Galantamine
Improvement
Caregiver time for instrumental ADLs (hr/month)
Community control
*Mixed model; p=0.0016 galantamine vs. control
Months 0 12 6
Galantamine 72 48 37
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Total costs
Grossly two areas of costs were investigated: direct cost
(trial medication, health care costs, social care costs, out-of-
pocket support paid by patients or caregivers, and accommo-
dation) and indirect costs (informal care and missed work of
caregiver). Direct costs and indirect costs were added together
to give a total cost. The total costs and their standard devia-
tions (SDs) per patient after 52 weeks were KRW 14,735,000
±10,238,000 (USD 12,315±8,557) for the galantamine
group and KRW 25,325,000±20,903,000 (USD 21,166
±17,470) for the control group (Table 2). Cost saving for
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Fig. 2. Mean change (standard error) over time from baseline in
activities of daily living (as assessed with the Disability Assess-
ment in Dementia Scale [DAD]).
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Patients evaluated (n)
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Galantamine 72 72 72 72 48 42 37
Community control 66 56 44
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Characteristics
Cost 
saving
� p
�
Galantamine
Baseline (n=72) Week 52 (n=45) *
Control
Baseline (n=66) Week 52 (n=45) *
Direct costs 6,522±3,083 9,159±3,566 +2,637 6,460±4,264 6,445±3,990 -15 -2,652 0.6404
Trial medication  0 1,465±503 +1,465 0 0 0 -1,465 -
Health care service  1,576±1,038 1,944±643 +368 213±293 358±400 +145 -223 0.0685
Social care service  329±1,601 1,055±2,726 +726 333±945 401±956 +68 -658 0.2882
Out-of-pocket support 703±2,404 877±1,826 +174 1,464±3,867 1,213±3,167 -251 -425 0.0889
Accommodation 3,915±728 3,818±658 -97 4,449±845 4,473±824 +24 +121 0.0015
Indirect costs 5,428±6,411 3,157±6,699 -2,271 8,970±11,260 14,721±16,323 +5,751 +7,992 0.0004
Caregiver patient care 5,218±6,210 2,806±6,613 -2,412 6,733±9,172 11,854±13,899 +5,121 +7,533 0.0054
Missed work  210±1,218 351±1,490 +141 2,237±3,237 2,867±3,934 +630 +489 0.0414
Total costs 11,950±7,428 12,315±8,557 +365 15,429±12,795 21,166±17,470 +5,737 +5,372 0.0089
Table 2. Costs of the long-term 52 week study population 
Values [USD] are expressed as mean±standard deviation unless otherwise indicated.
All the costs in this table are presented after conversion to 52-week costs by multiplying 6 to 2-month costs.
* , mean at week 52 mean at baseline; 
� Cost saving, change from baseline in the control group at week 52-change from baseline in the galantamine
group at week 52. A positive value indicates saving with galantamine. Monetary values are expressed as US dollars; 
� the GEE model was used to test
statistical significance between 2 groups in this longitudinal data analysis, using statistically different baseline characteristics as covariates (i.e., patient
age, caregiver age, and duration of formal education) and non-normal distribution (gamma distribution) for costs.Economic and Clinical Benefits of Galantamine in AD 15
galantamine treatment after 52 weeks compared with the
control group who had not taken galantamine during the
52-week study period (cost saving=change from baseline in
control group-change from baseline in the galantamine group),
can be estimated KRW 6,428,000±3,068,000 (USD 5,372
±2,564). This 52-week total cost saving was statistically
significantly different between the two groups when base-
line differences were adjusted (GEE: p=0.0089).
Direct costs
Direct costs were provided for all patients. Mean direct
costs and their SDs after 52 weeks for the galantamine group
were KRW 10,959,000±4,267,000 (USD 9,159±3,566)
per patient compared with KRW 7,711,000±4,773,000
(USD 6,445±3,990) per patient for the control group, result-
ing in an additional cost per patient of KRW 3,173,000±
3,493,000 (USD 2,652±2,919) (GEE; p=0.6404) (Table 2).
Following subcategory costs in the galantamine group in-
creased direct costs after 52 weeks; trial medication (KRW
1,753,000; USD 1,465), health care service (KRW 440,000;
USD 368), social care services (KRW 869,000; USD 726),
and out-of-pocket support (KRW 208,000; USD 174), while
accommodation cost in the galantamine group was signifi-
cantly decreased when compared to the control group (GEE;
p=0.0015) (Table 2). During the 2nd half of the 52-week
study, direct costs in the galantamine group were increased
(= +USD 781), while those in the control group were de-
creased ( =-USD 931) (GEE; p<0.0001). Death of 14 patients
who had used high costs in the control group contributed to
the widened gap in the direct costs (GEE; p<0.0001).
Indirect costs
Indirect costs were time-related in this study; time for car-
ing for the AD patients and time for missed work of the care-
giver. Indirect costs after 52 weeks for the galantamine group
were KRW 3,778,000±8,015,000 (USD 3,157±6,699)
per patient compared with KRW 17,614,000±19,530,000
(USD 14,721±16,322) per patient for the control group.
Adjusted cost saving was KRW 9,562,000±4,117,000
(USD 7,992±3,441) per patient for indirect costs (GEE; p=
0.0004) (Table 2). 
Sensitivity analyses
When costs were imputed for patients withdrawing from
the study prematurely (LOCF approach), the total cost after
52 weeks were KRW 14,297,000 (USD 11,949) for the galan-
tamine group and KRW 23,085,000 (USD 19,294) for the
control group. Adjusted cost saving for the galantamine treat-
ment after 52 weeks compared with the control group was
estimated KRW 4,626,000 (USD 3,866). This 52-week total
cost saving was statistically significantly different between
two groups (GEE: p=0.0007). Direct costs after 52 weeks for
the galantamine group were KRW 9,248,000 (USD 7,729)
per patient compared with KRW 8,137,000 (USD 6,800)
per patient for the control group, resulting in an additional
cost per patient of KRW 1,036,000 (USD 866) (GEE; p=
0.2336). Indirect costs after 52 weeks for the galantamine
group were KRW 5,049,000 (USD 4,219) per patient com-
pared with KRW 14,948,000 (USD 12,493) per patient for
the control group. Adjusted cost saving was KRW 5,662,000
(USD 4,732) per patient for indirect costs (GEE; p<0.0001). 
When we tested a range of unit cost of caring for a patient
per hour (-50% to +50% of KRW 6,250 [USD 5.22] per
hour), cost saving in total costs ranges from KRW 4,056,000
to 15,095,000 (USD 3,390 to 12,616) and cost saving in
indirect costs ranges from KRW 5,092,000 to 16,131,000
(USD 4,256 to 13,482). The magnitude of the difference in
costs obtained in these sensitivity analyses differed in the
main analyses, but the direction of the results did not alter.
These sensitivity analyses, therefore, confirmed the findings
of the main economic evaluation.
DISCUSSION
A 16-week trial of galantamine had demonstrated a supe-
rior efficacy relative to baseline and compared with the con-
trol group in the treatment of patients with mild to moder-
ate AD in a Korean population (5). The 52-week prospec-
tive study also demonstrated significant clinical improve-
ments relative to baseline and compared with the control
group. Results for the galantamine group was consistently
and statistically significantly superior to the control group.
This study extends the result of previous randomized stud-
ies that also showed beneficial effects of galantamine (5, 23-
26). Reduction in time caring for the patients and improve-
ment in functional capacity maintained during the 52-week
study period in the galantamine group, whereas greatly in-
creased caregiver time and progressive functional deteriora-
tions were observed in the control group. Difference in care-
giver time between two groups was equivalent to 9.4 (=[6.7
+68.8] hr/8 hr) working days per month or 112.8 working
days per year under the assumption that a person works 8 hr
a day (Fig. 1). Economic analyses of the 52-week prospective
study indicate that galantamine could reduce the overall cost
of caring for AD patients. When compared to no treatment,
estimated cost saving of galantamine treatment in total cost
averages KRW 6,428,000 (USD 5,372) per patient a year
(GEE, p=0.0089), while estimated additional, not statisti-
cally significant, direct costs average KRW 3,173,000 (USD
2,652) per patient a year (GEE, p=0.6404). 
Loss of autonomy due to disabled BADLs and IADLs is an
important determinant of quality of life and caregiver bur-
den. More rapid decline in IADLs was observed in moderate
AD than in mild AD, whereas basic ADLs were lost more16 G.-H. Suh, H.Y. Jung, C.U. Lee, et al.
rapidly in severe AD (27). As informal (unpaid) caregivers
have performed most of the care for patients with dementia
in Korea and soon they will inevitably place their relatives
in institutional care, valuing these efforts is an important
issue. The measurement and valuation of time spent caring
for patients with dementia pose a great challenge. In this
study, the amount of time spent caring for disabled BADLs
and IADLs were converted to part of indirect cost using a
replacement cost approach. It should not be considered that
family care is a cost-free alternative to institutional care. In-
stead, caregivers incur huge care burdens, including econom-
ic hardship, curtailment of social activities, emotional strain,
and psychological distress (28).
Clinical trials give necessary but not sufficient informa-
tion for judging the cost effectiveness of new treatment in
dementia. Drug efficacy data need to be combined with epi-
demiologic data that describe the natural progression of the
disease, with economic data to quantify resource use and costs,
and possibly also with quality-of-life data to estimate the
benefits of treatment to patients and to caregivers (29). This
study has a merit that epidemiologic data for natural progres-
sion had been included, so that all these results are more appro-
priate for pharmacoeconomic analyses. 
Direct costs in the galantamine group increased constant-
ly through 52 weeks, while that in the control group most-
ly remained unchanged. In the galantamine group, reduced
indirect costs offset the cost of trial medication (Table 2). If
this study had been performed in a society where better and
sufficient health and social care services for AD patients could
have been provided, cost of galantamine should have been
offset by reduced direct costs in health and social care ser-
vice like in previous studies (30, 31). In 2002, health and
social care services in Korea were greatly deficient. The insti-
tutional care capacity rate in Korea was 30% in 2003 (per-
sonal communication; Ministry of Health and Welfare). There-
fore, all these services were provided on a ‘first come, first
served’ basis. After study entry, patients in the galantamine
group began to use more health care services, more social care
services, and spent more on out-of-pocket expenses, whereas
patients and caregivers in the control group had done fewer
efforts to receive more health and social care services and even
reduced out-of-pocket expenses. Patients and caregivers of
the galantamine group had regularly visited memory clinics
for study interview and trial medication, while, in the con-
trol group, research psychologists visited patient’s home to
complete the study interview. Further, patients and caregivers
in the galantamine group were willing to take medical treat-
ment of AD, but those in the control group were not. These
different health behaviors and attitude appear to make two
groups greatly different. 
There are some limitations in this study. Firstly, as for any
clinical trials, the inclusion/exclusion criteria may limit the
ability to extrapolate the results of this study to the general
population. Secondly, using study design without a placebo
group. baseline characteristics were different in the galan-
tamine group and the control group. To adjust for the base-
line difference, cost savings were calculated using mean dif-
ference from week 52 to baseline and all the significantly
different patient and caregiver characteristics were included
in the statistical models to assess any effect on the dependent
variables. However, this limitation requires careful attention
to the methods employed in nonrandomized control studies
(32) and suggests that all results of such studies should be
considered in the light of data from relevantly controlled
trials. Thirdly, dropout rates were high in both groups dur-
ing 52-week study. A total of 138 patients enrolled in the
trial, 37 (51%) of the galantamine group and 45 (68%) of
the control group completed the 52-week prospective study.
Of 35 patients of the galantamine group who did not respond
to the final study interview at the 52-week study, 15 did not
visit without comments (but not dead or institutionalized),
2 hospitalized, 3 moved, and 15 refused to interview. Of the
21 patients in the control group who did not complete the
52-week study, 14 were dead, 2 institutionalized, 3 absent
during community survey period (n=3), and 2 refused the
interview. Although there was no statistically significant dif-
ferent demographic, clinical, and cost profiles between those
who completed and those who dropped out, this limitation
requires careful attention when we interpret results of this
study because those who dropped out might possibly cost
much more or much less than expected in case that they
remained to the end of the trial. Fourthly, the range of the
MMSE score (10 to 22) for recruitment criteria was not wide
enough to present study results according to the different
stage of dementia (i.e., mild, moderate). Further studies need
to be performed to make these results more useful for policy
decision makers.
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